New insomnia therapy for children: development of AI for therapy and proof-of-concept trial with Sheffield Children's NHS Foundation Trust

儿童新失眠疗法：与谢菲尔德儿童 NHS 基金会信托基金合作开发人工智能疗法和概念验证试验

• 批准号: 10072037
• 金额: $ 32.27万
• 依托单位: BRAINTRAIN2020 LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10072037
• 关键词: New; insomnia; therapy; children; development

The amount we sleep has been increasingly recognised as having an important impact on our health and well-being. Over recent years we have become increasingly aware of the effects that sleep has on both our physical and mental health. Even one bad night's sleep or late night can affect a person's mood, alertness and memory. The long-term effect of poor sleep can cause a range of life-threatening conditions such as cardiovascular disease, obesity and depression.However, insomnia is a global epidemic affecting up to 25% of children and 35% of adolescents with 43% suffering with insomnia into adulthood (Fernandez-Mendoza, 2022).Our mission is to rid the world of addictive sleeping tablets and provide a good night's sleep for everyone, improving health and well-being.SleepCogni has identified an urgent clinical need for a solution to support children due to the current lack of treatment options. SleepCogni provides an innovative technological solution to this problem. The wearable medical device delivers sleep therapy offering immediate relief when it's needed most. The patented Active-Biofeedback technology delivers personalised therapy and provides unique behavioural insights to make meaningful improvements. This patented technology uses haptic feedback to break the cognitive cycles that prevent sleep. Providing sleep clinicians with an economical and efficient technological solution to manage insomnia.SleepCogni now seek to develop and incorporate AI into our patented Active-Biofeedback therapy to improve the personalisation and engagement. Through our collaborators, Sheffield Children's NHS Foundation Trust, this will then be tested in children under 18 in a proof of concept trial to determine the efficacy and user experience.SleepCogni will act as a first-line therapy solution which will directly address the growing waiting lists, helping paediatric patients self-manage their insomnia alongside their family.

我们的睡眠量越来越被认为对我们的健康和福祉有重要影响。近年来，我们越来越意识到睡眠对我们身心健康的影响。即使是一个糟糕的睡眠或深夜也会影响一个人的情绪，警觉性和记忆力。长期睡眠不足会导致一系列危及生命的疾病，如心血管疾病、肥胖和抑郁症。然而，失眠是一种全球流行病，影响多达25%的儿童和35%的青少年，其中43%的人在成年后仍患有失眠症（费尔南德斯-门多萨，2022年）。我们的使命是让世界摆脱成瘾的安眠药，为每个人提供良好的睡眠，SleepCogni已经确定了一个迫切的临床需求，即由于目前缺乏治疗方案，需要一种解决方案来支持儿童。SleepCogni为这个问题提供了一个创新的技术解决方案。可穿戴医疗设备提供睡眠治疗，在最需要的时候提供即时缓解。专利的主动生物反馈技术提供个性化治疗，并提供独特的行为洞察力，以做出有意义的改进。这项专利技术使用触觉反馈来打破阻止睡眠的认知周期。为睡眠临床医生提供经济高效的技术解决方案来管理失眠。SleepCogni现在寻求开发并将AI纳入我们的专利主动生物反馈疗法，以提高个性化和参与度。通过我们的合作者，谢菲尔德儿童NHS基金会信托基金，将在18岁以下儿童中进行概念验证试验，以确定疗效和用户体验。SleepCogni将作为一线治疗解决方案，直接解决不断增长的等候名单，帮助儿科患者与家人一起自我管理失眠。